Abstract: The rate of NACT use has increased annually for advanced ovarian cancer in clinical practice. Neoadjuvant chemotherapy（NACT）for ovarian cancer is still controversial for many years，although patients received NACT followed by interval cytoreductive surgery had equivalent progression-free survival and overall survival compared with primary cytoreductive surgery among women with advanced stage ovarian cancer, with less surgical morbidity in randomized control studies.At present，the newly diagnosed ovarian cancer patients should be evaluated by gynecological oncologists and/or multi-disciplinary assessment if necessary.Primary tumor reductive surgery should be attempted priority to achieve satisfactory tumor resection after evaluation.However，neoadjuvant chemotherapy followed by interval tumor reductive surgery is an alternative approach for unresectable tumor or reductive surgery is not feasible.

Key words: advanced epithelial ovarian cancer, primary cytoreductive surgery, interval debulking surgery, neoadjuvant chemotherapy

摘要： 临床工作中对晚期卵巢癌患者施行新辅助化疗（neoadjuvant chemotherapy，NACT）的比例逐年增加。尽管基于现有的循证医学证据，晚期上皮性卵巢癌采用NACT联合间歇性肿瘤细胞减灭术有着不低于初始肿瘤细胞减灭术的疗效，更低的术后病率,但目前对于卵巢癌NACT仍存在较多争议。新诊断的晚期卵巢癌患者治疗前需由专业的妇科肿瘤医生（必要时多学科）评估，对可达到满意细胞减灭术患者应首选初始肿瘤细胞减灭术，对围手术期风险高和（或）无法达到满意肿瘤切除的晚期卵巢癌患者，可给予铂为基础的NACT联合间歇性肿瘤细胞减灭术。

关键词: 晚期上皮性卵巢癌, 初始肿瘤细胞减灭术, 间歇性肿瘤细胞减灭术, 新辅助化疗